다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

홈
인베스팅
주식
미국
NASDAQ
EyePoint Pharmaceuticals Inc (EYPT)
EyePoint Pharmaceuticals Inc (EYPT) 뉴스

EYPT

EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:EYPT

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/16	20:00	GlobeNewswire Inc.	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/05/09	23:12	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/05/09	05:23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/05/08	20:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/05/08	20:00	GlobeNewswire Inc.	EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/05/06	22:25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/05/06	20:00	GlobeNewswire Inc.	EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/04/16	20:00	GlobeNewswire Inc.	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/04/02	20:00	GlobeNewswire Inc.	EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/03/18	20:00	GlobeNewswire Inc.	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/03/09	03:53	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/03/07	21:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/03/07	21:00	GlobeNewswire Inc.	EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/03/05	07:40	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/03/05	07:37	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/03/04	21:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/03/04	21:00	GlobeNewswire Inc.	EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/02/29	21:00	GlobeNewswire Inc.	EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/02/27	21:00	GlobeNewswire Inc.	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/02/23	07:08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/02/16	21:00	GlobeNewswire Inc.	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/02/15	11:08	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/02/14	07:40	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/02/14	07:39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/02/14	07:38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/02/14	07:38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/02/14	07:37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/02/14	02:00	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/02/06	07:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc
2024/02/04	06:20	GlobeNewswire Inc.	EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration	NASDAQ:EYPT	EyePoint Pharmaceuticals Inc

검색 관련기사 보기:NASDAQ:EYPT

1 2 3 4 5 6 7 8 9 10 다음 >>

L&G Quality Eqty Div ESG...

Threshold Network Token

Westwater Resources

Hungary Tf 1,75% Ot27 Eur

ELETS300 Ex:29,6

Amundi Index Solutions

FTSE Italia All Share Re...

Glenville Bank (CE)

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관